Pillar 1: One billion more people benefiting from universal health coverage

11.7 Acceleration towards the Sustainable Development Goal targets for maternal health and child mortality

STATEMENT

Delivered by Hillary Mutungi

The Medicines Patent Pool recognises the importance of access to quality-assured and affordable medicines to reduce maternal and child mortality, and of the availability of optimal paediatric medicines in adapted formulations.

As a founding member of the Global Accelerator for Paediatric Formulations network, MPP welcomes the inclusion of two operational paragraphs addressing paediatric medicine formulations in the proposed resolution, marking a significant step forward in prioritising the needs of children.

MPP is also committed to enhancing access to essential medicines for maternal health, demonstrated by our recent memorandum of understanding and conditional licensing agreement with Ferring on access to heat-stable carbetocin for post-partum haemorrhage.

MPP remains committed to facilitating access to essential medicines in collaboration with WHO and Member States. Together, we can ensure that children and mothers receive the care they need, contributing to better health outcomes for future generations.

Pillar 1: One billion more people benefiting from universal health coverage

Agenda Item: 7

11.2 Follow-up to the political declaration of the third high-level meeting of the General Assembly on the prevention and control of non-communicable diseases

Prevention and management of noncommunicable diseases, promotion of mental health and well-being, and treatment and care of mental health conditions

The Director-General submits this report pursuant to the request of the Health Assembly in decision WHA72(11) (2019) on follow-up to the political declaration of the third high-level meeting of the General Assembly on the prevention and control of non-communicable diseases “to consolidate reporting on the progress achieved in the prevention and control of noncommunicable diseases and the promotion of mental health with an annual report to be submitted to the Health Assembly through the Executive Board, from 2021 to 2031, annexing reports on implementation of relevant resolutions, action plans and strategies, in line with existing reporting mandates and timelines”

STATEMENT

Delivered by Hillary Mutungi

The Medicines Patent Pool (MPP) welcomes the opportunity to comment on the report on the follow-up to the political declaration from the third high-level meeting on the prevention and control of NCDs[1] and notes that improving availability of affordability of essential medicines, including generics, is a key element of the document.

MPP is dedicated to accelerating access to innovative essential medicines in their generic and biosimilar versions through voluntary licensing and technology transfer, to improve affordability, availability and to support regional manufacturing.

To achieve this, MPP remains committed to collaborating with WHO, Member States, and other stakeholders to identify priorities, create a favorable environment for licensing and technology transfer and support the achievement of universal health coverage.

[1] https://apps.who.int/gb/ebwha/pdf_files/EB154/B154_7-en.pdf

Pillar 2: One billion more people better protected from health emergencies 

13.3 Working Group on Amendments to the International Health Regulations (2005)

13.4 Intergovernmental Negotiating Body to draft and negotiate a WHO convention, agreement or other international instrument on pandemic prevention, preparedness and response

STATEMENT

Delivered by Tiwa Braimoh

As an organisation dedicated to improving access to affordable innovative medicines and other health technologies in low- and middle-income countries, the Medicines Patent Pool (MPP) is pleased to observe the consistent recognition of the importance of ensuring timely and equitable access to pandemic-related products all through the WGIHR and INB processes.

MPP would like to commend the efforts of the leadership of the two processes and all stakeholders and hopes that the negotiations will resume and be concluded soon.

In the meantime, MPP remains available to offer support in anyway needed, including sharing from its experience and expertise in licensing as well as its work with the WHO on the mRNA Technology Transfer programme.